Center-Authored Papers

Filters: Author is Bailer, Robert T  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
T
Casazza JP, Bowman KA, Adzaku S, Smith EC, Enama ME, Bailer RT, Price DA, Gostick E, Gordon IJ, Ambrozak DR et al..  2013.  Therapeutic Vaccination Expands and Improves the Function of the HIV-Specific Memory T-Cell Repertoire.. The Journal of infectious diseases. Abstract
Karasavvas N, Billings E, Rao M, Williams C, Zolla-Pazner S, Bailer RT, Koup RA, Madnote S, Arworn D, Shen X et al..  2012.  The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120.. AIDS research and human retroviruses. 28(11):1444-57. Abstract
S
Zhou T, Lynch RM, Chen L, Acharya P, Wu X, Doria-Rose NA, Joyce GM, Lingwood D, Soto C, Bailer RT et al..  2015.  Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors.. Cell. Abstract
P
Gottardo R, Bailer RT, Korber BT, Gnanakaran S, Phillips J, Shen X, Tomaras GD, Turk E, Imholte G, Eckler L et al..  2013.  Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial.. PloS one. 8(9):e75665. Abstract
M
Doria-Rose NA, Altae-Tran HR, Roark RS, Schmidt SD, Sutton MS, Louder MK, Chuang G-Y, Bailer RT, Cortez V, Kong R et al..  2017.  Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting.. PLoS pathogens. 13(1):e1006148. Abstract
I
Kong R, Louder MK, Wagh K, Bailer RT, DeCamp A, Greene K, Gao H, Taft JD, Gazumyan A, Liu C et al..  2015.  Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes.. Journal of virology. 89(5):2659-71. Abstract
Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam MS, Evans DT, Montefiori DC, Karnasuta C, Sutthent R et al..  2012.  Immune-correlates analysis of an HIV-1 vaccine efficacy trial.. The New England journal of medicine. 366(14):1275-86. Abstract
H
Prentice HA, Tomaras GD, Geraghty DE, Apps R, Fong Y, Ehrenberg PK, Rolland M, Kijak GH, Krebs SJ, Nelson W et al..  2015.  HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition.. Science translational medicine. 7(296):296ra112. Abstract
G
DeCamp A, Hraber P, Bailer RT, Seaman MS, Ochsenbauer C, Kappes J, Gottardo R, Edlefsen P, Self S, Tang H et al..  2014.  Global Panel of HIV-1 Env Reference Strains for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies.. Journal of virology. 88(5):2489-507. Abstract
C
Imholte GC, Sauteraud R, Korber B, Bailer RT, Turk ET, Shen X, Tomaras GD, Mascola JR, Koup RA, Montefiori DC et al..  2013.  A computational framework for the analysis of peptide microarray antibody binding data with application to HIV vaccine profiling.. Journal of immunological methods. Abstract
Quinn KM, Da Costa A, Yamamoto A, Berry D, Lindsay RWB, Darrah PA, Wang LS, Cheng C, Kong W-P, Gall JGD et al..  2013.  Comparative Analysis of the Magnitude, Quality, Phenotype, and Protective Capacity of Simian Immunodeficiency Virus Gag-Specific CD8+ T Cells following Human-, Simian-, and Chimpanzee-Derived Recombinant Adenoviral Vector Immunization.. Journal of immunology (Baltimore, Md. : 1950). 190(6):2720-35. Abstract
A
Zolla-Pazner S, Decamp AC, Cardozo T, Karasavvas N, Gottardo R, Williams C, Morris DE, Tomaras G, Rao M, Billings E et al..  2013.  Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial.. PloS one. 8(1):e53629. Abstract